Diabetic Nephropathy – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs intended to halt the progression of kidney damage associated with diabetes. By demonstrating a significant reduction in the relative risk of a renal-specific composite endpoint, Invokana became the first antidiabetic drug to demonstrate a renoprotective effect in a dedicated renal outcomes trial. The SGLT-2 inhibitor has opened the door for this drug class to be used to lower eGFR limits, potentially shifting treatment patterns in this market. Bayer’s Kerendia, a first-in-class mineralocorticoid receptor antagonist, was recently approved by the FDA to slow the progression of DN.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed DN patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed DN patients?
- How have Kerendia and SGLT-2 inhibitors such as Invokana and Farxiga been integrated into the treatment algorithm, and what is their source of business?
- What percentage of DN patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of DN patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Table of contents
- Diabetic Nephropathy - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms CDA Diabetic nephropathy US June 2022
- Treatment Algorithms CDA Diabetic nephropathy US 2022 Dashboard
Manasa Kadagathur, M.S. (Pharm.), Ph.D., is a research associate on the Cardiovascular, Metabolic, Renal, and Hematologic Disorders team at Clarivate. She holds an M.S. (Pharm.) degree in medicinal chemistry from the National Institute of Pharmaceutical Education and Research (NIPER) in S.A.S. Nagar, India, and a bachelor’s degree in pharmacy from Jawaharlal Nehru Technological University in Hyderabad, India. She earned her Ph.D. in medicinal chemistry from NIPER in Hyderabad, India.